Pancreatic Cancer Pathology Research

Alfa Cytology is a CRO company comprised of scientists, oncologists, and bioinformaticians. We are dedicated to helping researchers and professionals understand pancreatic cancer (PC) biology, explore new pancreatic cancer therapeutics and strategies, and develop new pancreatic cancer biomarkers.

Overview of Pancreatic Cancer

Pancreatic cancers are broad-spectrum and are usually classified into epithelial and non-epithelial based on their histological differentiation. Epithelial neoplasms can be endocrine or exocrine; the exocrine tumor group is further divided into alveolar and ductal neoplasms. Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic malignancy,  accounting for >95% of deaths from pancreatic cancer. Therefore, as the most common type of pancreatic cancer, PDAC is usually referred to as pancreatic cancer.

Fig. 1 Stages of metastatic progression in pancreatic cancer. (Miquel, M.; et al., 2021)

PDAC has three best-characterized precursors that have unique clinical, pathological, and molecular features, including intraductal papillary mucinous neoplasms (IPMN), pancreatic intraepithelial neoplasia (PanIN), and mucinous cystic neoplasms (MCN). Approximately 60-70% of pancreatic cancer occur in the head of the pancreas, with the remainder arising in the body (15%) and tail (15%) of the pancreas.

Histomorphology of Pancreatic Cancer

pancreatic cancer consists of atypical tubular glands resembling medium or smaller pancreatic ducts. The growth pattern is different between and within tumors. Irregular pancreatic cancer tumor glands usually embed a significant desmoplastic stroma composed of stromal cells, inflammatory cells, and extracellular matrix proteins and contribute to the aggressive biological behavior of this tumor. Histopathological grading of pancreatic cancer serves as an important factor in prognostication, judged by criteria involving the presence of mucins, nuclear polymorphism, the number of mitoses, and the comparison of the tubular structure and solid growth.

Fig. 2 Pancreatic cancer develops from well-defined precursor lesions.. (Luchini, C.; et al., 2019)

Our Services

Alfa Cytology greatly improves our customer's understanding of pancreatic cancer pathology. We offer biospecimens collection and processing, histology, immunostaining, and imaging services to support basic and translational pancreatic cancer research projects. Based on advanced platforms and years of experience in the pancreatic cancer field, we are committed to providing our customers with optimal customized services to meet the specific needs of their projects.

Pathological Technology Platform

Alfa Cytology has an advanced pathology experimental platform to provide our customers with extensive and reliable experimental programs.

Why Choose Us

Scientific Excellence Customized Solutions Collaborative Approach Worldwide Service Data
Security

Alfa Cytology provides pathology research services for pancreatic cancer. Contact us immediately to explore how our R&D services can pave the way for your project. Our team of experts will contact you within one business day to discuss your needs.

References

1. Miquel M,; et al. Pre-clinical Models of Metastasis in Pancreatic Cancer. Front Cell Dev Biol. 2021;9:748631. Published 2021 Oct 27. doi:10.3389/fcell.2021.748631
2. Luchini C,; et al. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Mod Pathol. 2019;32(5):659-665. doi:10.1038/s41379-018-0183-7